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INTRODUCTION
Fertility preservation and pregnancy in 
survivors of gynaecologic cancer are becoming 
more important since women delay 
childbearing and progress in medicine has had 
1positive impact on cancer survival .The 
improvement in surveillance and treatment of 
cancer in recent years result in decreased 
mortality among the patients. About one in 650 
children below 15 years of age are diagnosed 
with cancer every year, with five year survival 
2rate exceeding 75% in most cases . In the USA, 
72,000 adolescents and young adults defined as 
people aged 15-39 years were diagnosed with 
3cancer in 2006 . The consequences of these are 
the long term outlook of treatment related 
morbidity and quality of life issues, not the least 
fertility related issues. Cancer survivors 
particularly the young ones face the challenges 
of resuming life with the same quality of life as 
before the diagnosis and treatment of the 
cancer. Evidence is abound that diagnosis of 
cancer in this age group interferes with their 
ability to complete education, develop a career, 
4, 5remain employed or maintain relationship . 
Indeed various organs may be irreversibly 
affected as a direct consequence of treatment 
causing other health challenges.
On the whole cancer diagnosis and treatment 
adversely affects the quality of life of survivors 
often irreversibly. Clearly this would depend 
on age at which cancer treatment is given on 
one hand, the type as well as the scope of the 
treatment given on the other. For instance the 
ovarian reserve has been shown to be impaired in 
dose –dependent manner among cancer 
survivors compared with females of similar age. 
Reproductive hormone levels in menstruating 
survivors exposed to high dose therapy are 
6similar to those in late reproductive years . For 
young people reproductive health issues are a 
specific concern especially as relates altered 
endocrine function and fertility and the 
associated psychosocial effects that comes to 
7bear . Treatment methods with clear survival 
benefit are often toxic to the gonads, as in the 
case of high dose alkylating agents and 
irradiation of the pelvis usually used alone or in 
combination with surgery. The possibility of 
reproductive dysfunction in young women with 
cancer has a recognised link with depression, 
post-traumatic stress and psychosocial 
problems. A survey among young adults with 
breast cancer shows correlation between 
reproductive concerns and depressive 
8, 9, 10symptoms .
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The scope of reproductive dysfunction 
associated with cancer therapy varies widely 
depending on the treatment method or 
combination of methods, the type and stage of 
the cancer as well as the age at treatment and 
reproductive wishes of the patient. Both male 
and female reproduction can be compromised. 
In the case of the male the most frequently 
employed fertility preservation strategy is in 
vitro cryopreservation of sperm which is often 
obtained none invasively. The challenges of 
obtaining mature female gametes are obvious 
limitations for this technique in the female 
thereby compounding the problem further. 
Gynaecologist, particularly oncologist have a 
duty of care in educating and sign posting young 
cancer patient on the reproductive effects of 
therapy, strategies for fertility preservation and 
respective measures of reproductive reserve. 
Evidence however points to the contrary that 
these patients seldom receive sufficient 
11, oncofertility counselling from their providers
12. Oncologist themselves posit that they seldom 
discuss fertility preservation with the patients 
nor refer them to reproductive medicine 
services. Among reasons for this approach are 
the focus on the treatment of the cancer as top 
priority and anxieties about delay to treatment, 
lack of training in fertility measures and 
preservation methods and the perception that 
any such discussion only increases stress to the 
patients. A survey of Irish Gynaecology 
oncologist in 2011, elicited poor awareness of 
the success rates of reproductive therapy, the 
estimated time delays to cancer treatment 
occasioned by fertility saving interventions 
among responders and identified barriers to 
oncofertility referral to include: time delay, poor 
prognosis and clinical features of the 
13cancer .This review examined the common 
reproductive morbidities associated with cancer 
treatment in young female cancer patients, 
outline the various fertility preserving measures 
and the various methods of assessment of 
reproductive reserve.
Reproductive Morbidity Associated With 
Cancer Treatment
At birth the female infant has about 2 million 
primodial follicles in the ovary, this rapidly 
regress through atresia such that at puberty the 
count is down to about 600000. Subsequent 
progressive depletion with each ovulation 
results in menopause when the count is down to 
7about a thousand, usually at the age 52 years . 
Fac to r s  such  as  su rge ry,  cy to tox ic  
chemotherapy, irradiation, genetic, hereditary 
and immunological are known to accelerate 
follicular atresia. Similarly these factors may 
have debilitating effect on spermatogenesis in 
the young male. A host of these factors are 
associated with cancer treatment. Table I, shows 
the common cancers in young people and their 
standard mode of treatment.
Table I: Common Cancers in Young People and 
Their Mode of Treatment
Cancer Standard therapy
Germ cell tumors of the ovary
 
Surgery and multi agent chemotherapy
Burkitt’s lymphoma
 















Wilm’s tumour Surgery and radiotherapy
74
Trop J Obstet Gynaecol, 30 (2), August 2013
Modalities of treatment vary in their effect, 
chemotherapy and radiotherapy may 
potentially affect all systems while surgery 
tends to be local in its effect and as such can be 
modified to limit reproductive side effects 
depending on the stage and type of cancer. 
Common effects of multi-agent chemotherapy 
in combination with surgery or radiotherapy 
include: cardiac and renal impairment, 
abnormal pulmonary function, and secondary 
malignancy. Reproductive effects are impaired 
gonadal function, endocrine function resulting 
in growth and abnormal puberty, infertility, 
14osteoporosis and psychosocial problems .
The impact of radiotherapy on ovarian function 
is variable depending on the dose, duration and 
frequency of exposure on one hand and the age 
of the patient at the time of exposure. Effect is 
mostly seen in dividing cells, thus as the 
primodial follicles in children and adolescents 
are in quiescent prophase I of meiosis, they are 
relatively resistant to irradiation than cells in 
mitosis in adult population. Nevertheless the 
LD50, defined as the dose of irradiation 
required to destroy 50% of immature follicles at 
2GY is relatively small, follicular damage still 
ensues. Younger cancer patients are known to 
tolerate exposure to irradiation more than 
15, young adults . Alkylating agents break the 
DNA in all stages of the cell cycle and are 
16particularly gonadotoxic . Similarly evidence 
exist that exposure to radiotherapy may affect 
the uterine capacity to support development of 
the fetus in the long term with increase in 
adverse pregnancy outcomes like miscarriage, 
abnormal placentation, preterm delivery and 
17intrauterine growth restriction .
Premature Menopause
Exposure to cytotoxic agents and/or irradiation 
18is a recognised cause of acute ovarian failure . 
Premature menopause is the occurrence of 
amenorrhoea, hypoestrogenism and elevated 
levels of gonadotropins before the age of 40 
years. This is associated with early and often 
times unexpected loss of reproductive potential 
and ovarian sex hormones with attendant 
cardiovascular, bone and psychosexual 
complications. 
Premature menopause may represent the end of 
spectrum of ovarian failure. In its occult form 
women present with unexplained loss of fertility 
with normal levels of gonadotropins in contrast 
to biochemical ovarian insufficiency commonly 
described in patients with unexplained infertility 
and elevated levels of follicle stimulating 
hormone (FSH). Both categories of these 
patients may maintain some measure of 
menstrual function. Whereas in overt ovarian 
failure elevated basal levels of FSH are seen in 
patients with oligomenorrhea or amenorrhea and 
loss of reproductive function. Complete 
depletion of primodial follicles result in 
irreversible infertility, amenorrhea and 
markedly elevated FSH (>30mmol/L). It is 
pertinent to note the progress in this continuum 
is unpredictable but can be accelerated by cancer 
therapy. Where the ovarian failure precedes 
puberty other physiological processes like 
19growth may be affected .
Clinical diagnosis is heralded by primary or 
secondary amenorrhea, abnormal development 
of secondary sexual characteristics or infertility 
in the older woman and vasomotor symptoms of 
oestrogen deficiency. Endocrine studies relate to 
high levels of follicle stimulating and luteinising 
hormones and low levels of oestrogens. It is 
important to differentiate treatment induced 
premature menopause from autoimmune and 
genetic related causes where the clinical course 
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19, 20of the disorder may be intermittent . In the 
later case sexually active women not desirous of 
family may still require contraception if 
unwanted pregnancy is to be avoided. The 
combine oral contraceptive pills (COCP) lend 
themselves well for this purpose, as it provide 
bone protective effects as well as the 
psychological benefit of monthly withdrawal 
bleeding mimicking normal menstruation. In 
women who wish to avoid menstruation this can 
be taken back to back to obviate withdrawal 
bleed.Universal use of the COCP for HRT 
should be mindful of the different doses of 
steroid hormones in the two preparations and is 
cautioned against by some endocrinologists. 
Alternatives to the COCP among post treatment 
patients or where unwanted pregnancy is not a 
concern is cyclical combine hormone 
replacement therapy (HRT) or continuous 
combine HRT in patients that seek to avoid 
7withdrawal bleeds . Indeed patients without the 
uterus could use the oestradiol transdermal 
system (Alora) also known as oestrogen patches 
with similar short and long term benefits. It is 
prudent to bear in mind the psychological 
impact of using HRT in young women which 
constantly serve as a reminder to the cancer and 
its consequences. The use of the mirena 
intrauterine system in combination with weekly 
oestrogen patches achieves the same effect 
while seeking to limit this psychological impact. 
Women averse to taking hormones may use 
tibolone which is beneficial to vasomotor 
symptoms and is bone protective.
Patients with premature menopause have lower 
levels of testosterone, but only 13% have levels 
below the reference ranges.  Hence androgen 
replacement therapy is only offered in selected 
patient groups: those with persistent fatigue, low 
libido and poor well being despite adequate 
HRT in the absence of depression and thyroid 
disease. Methyl testosterone 1.25-2.5mg per day 
or parenteral testosterone esters 50mg every six 
weeks are in common use as does subcutaneous 
21slow release preparations every six month .
The concept of premature menopause is quite 
difficult for some women to accept, 
necessitating continuing counselling and 
support. It is best managed in a multidisciplinary 
team, for monitoring of treatment response, 
bone density and psychosexual concerns.  
Yearly monitoring of bone density using duel 
energy x-ray absorptiometry (DEXA) scans, 
nutritional and lifestyle issues as relates to 
e x e r c i s e ,  s m o k i n g  a n d  c a l c i u m  
supplementation. Measures of ovarian reserve 
should be employed to provide patients with 
objective fertility counselling and aid the use of 
fertility preserving measures.
Infertility
Spontaneous fertility ensues in the presence of 
intact and normally functioning neuroendocrine 
system, responsive follicular pool that produces 
fertilisable gamete and receptive uterine milieu 
capable of supporting implantation of the 
embryo and nurturing fetal growth to term. 
Cancer treatment,especially radiotherapy and 
chemotherapy adversely affects all aspects 
requisite to spontaneous fertility to a variable 
extent. Indeed some chemotherapeutic agents 
are directly fetotoxic necessitating the use of 
contraception during cancer chemotherapy in 
young women.
Closely related to acute ovarian failure 
following cancer treatment is anovulatory 
infertility in patients who had chemotherapy or 
high dose irradiation. Wallace et al reported on 
the radiosensitivity of the human oocyte. The 
LD50 for human oocyte is 2Gy, and with a 
radiation dose >5Gy 95% of 2000 women had 
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22permanent amenorrhoea . Similarly the impact 
of chemotherapy particularly non cycle specific 
a g e n t s  l i k e  t h e  a l k y l a t i n g  a g e n t  
cyclophosphamide is well established. 
Amenorrhoea rates up to 80% have been 
reported with radical chemotherapy, although 
the out look is more favourable when young 
23patients receive adjuvant chemotherapy .
Of course if treatment involved a hysterectomy, 
adoption and surrogacy remains the only means 
of having a family. Various measures have been 
employed to preserve fertility among young 
women receiving high dose chemotherapy 
and/or radiotherapy. Fertility conserving 
surgery has long been in practice before the 
advent of oncofertility. These include surgical 
transposition of the ovaries out of prospective 
radiotherapy field to limit irradiation damage, 
removal, cryopreservation and subsequent 
transplantation of ovarian tissue and in vitro 
maturation of oocyte. These will be considered 
in detail under fertility preservation. Hormonal 
treatment with progestogens in early stage 
endometrial cancer increasingly common in 
young women is employed temporarily in 
selected patients to delay sterilising treatment 
for purposes of child bearing. Other more 
established methods are cryopreservation of 
embryo and oocytes.
Preservation of Female Fertility
Infertility following cancer treatment is a 
recognised quality of live issue in survivors and 
effort should be made to help young cancer 
24patients retain their fertility .The field of 
fertility preservation strategy is ever expanding 
with an array of options coming into clinical 
practice from laboratory research. These range 
from the well established methods in routine 
clinical practice like in vitro fertilisation and 
freezing of embryo to developmental methods 
like invitro egg maturation. In this review these 
will be examined with emphasis to their present 
applicability in current oncofertility practice and 
the evidence base for their effectiveness where 
available.  In general the application of this 
methods depend on the age of the patient, state of 
puberty, type of cancer, ovarian reserve prior to 
therapy, intensity of cancer treatment, type, 
25duration and frequency of treatment . 
Embryo cryopreservation is the standard method 
26in clinical practice . Embryo freezing, 
subsequent thawing and invitro fertilisation 
(IVF) is a routine procedure in fertility clinics 
with well established effectiveness. Patients are 
hyperstimulated prior to treatment, to produce 
oocytes which are subsequently collected, 
fertilised invitro or by intracytoplasmic sperm 
injection (ICSI) and the resulting embryo 
cryofrozen (slow freezing or vitrification) and 
stored for future use. It presupposes that the 
patient is in a stable relationship, or prepared to 
accept donor sperm from identified or 
anonymous donor. Potential constraint here 
includes ethical, legal, cultural and religious 
considerations. Furthermore, this is appropriate 
for the post-pubertal patient but its applicability 
in younger patients is limited by the immaturity 
25of the gamete . The effectiveness of this method 
and identified constraints apart, oncologist have 
always been weary of the time delay that these 
procedures take and its potential impact on 
patient care and outcome of treatment. The effect 
of the medications used on the biological 
behaviour of different tumors is not exhaustively 
enunciated and remain a source of reservation 
for some. 
Oocyte cryopreservation presently considered 
experimental remain a potential option for the 
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patient not in a stable relationship, those whose 
male partners withhold consent for creating 
embryo, those who themselves decline the 
option of creating embryo or women that are in 
relationship yet seek to maintain reproductive 
27independence . The procedure involves 
hormone stimulation of the ovaries prior to 
treatment to produce multiple ova. These are 
then collected and frozen for future use. The 
evidence base in terms of its effectiveness for 
subsequent utilisation to produce embryo is less 
robust, its potential nonetheless make it a viable 
option in these category of patients. Most 
fertility services will require local ethical board 
approval to provide this method of treatment this 
however shouldn't be a deterrent in the context 
of the oncology patient. Some fertility clinics 
have achieved comparable pregnancy rates with 
frozen as fresh eggs in invitro fertilisation. 
In a recent multicentre observational study in 
450 couples, 2721 oocytes were wormed, of 
which 2304 (84.7%) survived cryopreservation 
and 2182 treated with ICSI. Fertilization rate 
was 75.2%, 48.1% of the embryos were of top 
quality and the delivery rate was 26.3%. In fact 
when this data was stratified by recursive 
partitioning analysis the delivery rate increased 
to 46.4% in cases where more than 8 oocytes 
28were vitrified . This led the authors to 
recommend its routine use in clinical practice.
Beside issues of consent, egg freezing is only 
applicable in those patients who can delay 
cancer treatment to allow for ovarian 
stimulation and egg collection (typically 2-5 
weeks) and tumors in which hormones can be 
used. In the others as in prepubertal girls, 
ovarian tissue or whole ovary cryopreservation 
is an alternative.
Ovarian or ovarian tissue cryopreservation is an 
alternative for women in whom hormonal 
stimulation is contraindicated or cancer 
treatment can not be delayed owing to the stage 
or cancer type. Ovarian cortical strips are taken 
cryopreserve or in instances the whole ovary is 
cryopreserved. This can be subsequently 
t r a n s p l a n t e d  b a c k  t o  t h e  p a t i e n t  
autotransplantation or in instances where the 
risk of transplanting cancer cells back to the 
patient is a concern, eggs are isolated matured in 
vitro and fertilised and the resulting embryo 
transferred in standard manner or to a surrogate 
mother as appropriate. There is sufficient 
evidence for restoration of hormonal and 
fertility functions with autotransplantation of 
cryopreserved ovarian tissue. However the 
evidence base for invitro follicular maturation is 
rather tenuous and the method is limited to 
research setting. Recently Oktay et al reported 
consecutive spontaneous viable pregnancies 
a f t e r  h e t e r o t r o p i c  o v a r i a n  t i s s u e  
29transplantation .
Surgical methods like ovarian shielding and/or 
transposition to limit the effect of irradiation 
27have been employed with varying outcome . 
Data  i s  ra ther  sparse  to  a l low for  
recommendation. In rare cases of genetic 
cancers, preimplantation genetic diagnosis has 
been employed in the context of these services to 
limit the risk of transmitting oncogenic 
7gametes . These techniques are successfully 
used to screen for cancer predisposing 
syndromes like BRCA gene for breast and 
ovarian cancer, von Reckulin hausen's disease 
and adenomatous polyposis colon the precursor 
of Lynch II syndrome.
The use of GnRH analogues to suppress 
ovulation is commonly used in oncology 
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practice during potentially toxic chemotherapy 
to protect primodial follicles containing 
27oocytes from damage . Rachia et al treated 100 
women with early breast cancer with GnRH 
analogues for 12 months during adjuvant 
chemotherapy; all the patients under the age of 
40 years recovered menstrual function and 
overall 67% return of menstruation was 
observed. The pregnancy rate was however low 
30at 3% .
Patients intending on the use of oncofertility 
services for preservation of their fertility 
require extensive counselling. This is best 
offered in specialised centres. Areas of focus 
should include the limited success rate of ART 
within none cancer and in cancer population, 
side effect of the cancer treatment including 
potential effect on developing fetus and impact 
on the capacity of the uterus to nurture a 
pregnancy to term in the case of radiotherapy 
and surgical methods like radical trachilectomy. 
Rare congenital defects known to be associated 
with birth resulting from these technologies like 
A n g e l m a n  s y n d r o m e  a n d  m a t e r n a l  
hypomethylation should be covered. The 
assessment of ovarian reserve prior to but 
particularly after treatment allows for a more 
objective fertility prognosis counselling.
Measures of Ovarian Reserve
The functional capacity of the ovary reflected 
by the number and quality of oocytes is known 
as ovarian reserve. Wide range of tests exist all 
aimed at predicting the fertility potential or 
possibilities either prior to or after cancer 
treatment. Tests carried out before treatment 
helps to select patients eligible for fertility 
preserving procedures in those deemed to have 
diminished reserve. Post-treatment test apart 
from providing fertility prognosis may help in 
deciding the prospect of spontaneous fertility or 
whether fertility preserving measures when used 
before treatment should be used to achieve 
31conception . It is instructive that these tests 
share as an end point the fertility potential, 
whereas fecundity should ideally be measured, 
especially as some treatment modes 
compromises the ability of the uterus to nurture a 
pregnancy to term. Fecundity test are still to be 
developed.
Available tests are broadly categorised into static 
and dynamic tests of ovarian reserve. Static tests 
assess biochemical and ultrasound parameters of 
ovarian reserve at a given point in time. Dynamic 
tests assess the ovarian response to exogeneous 
stimulation and involve measurement of 
hormones before and after the stimulation. The 
evidence base for various test vary in clinical 
practice and will be examined thus. 
Ovarian antral follicle count (AFC) in 
combination with antimullarian hormone 
(AMH) is the most common static tests for 
which evidence abound. AMH is produced by 
granulosa cells in developing follicles. In natural 
ageing AMH levels rises at around age 37 when 
the woman's follicular count is in the region of 
25000. In regularly menstruating women AMH 
is the endocrine factor most predictive of 
transition to menopause in four years and 
inversely correlates with the number of antral 
32follicles in the ovary . The mean antral follicular 
count in regularly menstruating women with no 
fertility concerns is usually high. Low AFC 
counts are associated with high levels of AMH 
and diminished fertility potential. The number of 
antral follicles correlates best with the ovarian 
age. The role of AFC and AMH combined is well 
established in clinical practice as a measure of 
the number of primodial follicles independent of 
the patient's age and are surrogates for ovarian 
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age and functional reserve.
The use of AMH and AFC as a measure of 
ovarian reserve has been effectively integrated 
33in oncofertility practice . High correlation 
between AMH and AFC is reported in post-
treatment patients. Levels of both of which are 
significantly lower than in cancer treatment 
exposed cohorts compared to controls. Indeed 
evidence exists in longitudinal studies that 
showed a marked decrease in AFC and AMH 
33following cancer therapy . These tests are in the 
core of static measures of ovarian reserve with 
robust evidence base. Others include ovarian 
volume, baseline day 1-5 FSH, oestradiol, and 
inhibin B; but the evidence base for these 
measures is quite limited except possibly for 
34ovarian volume . 
Dynamic tests in clinical practice are 
clomiphene citrate challenge test (CCCT), 
GnRH agonist stimulation test (GAST) and 
exogenous FSH ovarian reserve test (EFORT). 
First described in 1987 by Navot et al CCCT 
involves administration of 100mg of 
clomiphene citrate from day 5-9 of the cycle and 
measurement of FSH levels on days 3 and 10. 
Abnormally high levels of FSH, defined as 
levels >10U/L correlates well with poor 
pregnancy rates and cycle cancellation in IVF 
patients. A recent metanalysis of 5 studies 
concluded that the post test prediction of no 
pregnancy for CCCT at cut-off FSH >10U/L 
350.81 (95% CI 0.71-0.92) . 
GAST was described by Padilla et al 1990, it 
aimed at eliciting a dose response curve rather 
than normal or abnormal results seen with other 
measures. This depends on pituitary production 
of FSH and LH to stimulate follicular 
development in the ovary the measure of which 
indicates the follicular reserve. In EFORT 
recombinant FSH is used to induce follicular 
growth in the ovary, this method was first 
reported by Fanchin et al 1994; basal oestradiol 
and FSH are compared with post injection levels 
to assess the ovarian reserve. Maheshwari et al 
in a recent systematic review were unable to 
arrive at conclusion on the predictive ability of 
35GAST or EFORT .
Other Reproductive Effects of Cancer 
Treatment
The British childhood cancer survivor survey, 
studied pregnancy outcomes in both male and 
females survivors and their partners. Overall 
live birth rate among female survivors was two-
third of expected. Out of 4113 singleton 
pregnancies in the female survivors, 72.9% 
resulted in live birth, 14.8% miscarriage, 11.8% 
termination and 0.6% still birth. The incidence 
of low birth weight and preterm delivery among 
the live born babies for whom records were 
available were 9% and 14% respectively. The 
termination rate amongst survivors of heritable 
retinoblastoma was up to 70% and was largely 
premised in the fear of transmitting the RB1 
gene to the off spring. All spontaneous 
miscarriages attributable to the treatment 
36exposure were observed after 12 weeks .
Preterm labour and low birth weight were 
particularly observed in survivors exposed to 
pelvic or abdominal irradiation as opposed to 
those treated with brain radiotherapy. Uterine 
artery Doppler studies out with pregnancy 
demonstrated reduced blood flow in radiation 
exposed uterus a factor possibly accounting for 
low birth weight. Similarly the compliance and 
distensibility of the uterine myometrium is 
impaired by radiotherapy exposure leading to 
late miscarriage and preterm delivery. These 
adverse pregnancy outcomes are not observed in 
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female partners of male childhood cancer 
survivors.
Psychosexual Problems
Although studies on psychosocial behaviour in 
emerging adulthood that compare cohorts 
exposed to cancer therapy in childhood and 
adolescent with age matched cohorts are 
reassuring in terms of social self-concept, social 
competence, family relationship, friendship 
and romantic relationships the incidence of 
such activities is significantly less in treated 
compared to  the  unexposed group.  
Furthermore, treatment intensity and time since 
diagnosis are associated with impaired 
adjustment indices. The cohorts compared well 
in their intention to get married and have 
5
children . 
Similarly there is tendency to increased rates of 
post traumatic stress symptoms and 
psychological distress in exposed adolescents 
and young adults. Indeed the physical effect of 
radiotherapy on vaginal tissue may impact 
sexual function and affect relationships. 
Similarly changes in body image, diminish 
sense of sexuality occasioned by premature 
menopause, surgically induced body changes 
and related altered endocrine function 
adversely affect libido, self image, sexual 
dysfunction and relationship confidence 
including loss of attractiveness in the affected 
patients. 
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